AstraZeneca lines up finance chief Dunoyer to head Alexion

AstraZeneca said on Friday it had appointed Alexion's Aradhana Sarin as its new chief financial officer as it shifts existing CFO Marc Dunoyer to a new role leading the U.S.-based drugmaker after the pair's merger.

AstraZeneca agreed to buy Alexion in December in its largest-ever deal, a bet on rare-disease immunology which also includes a fast-growing cancer medicines unit and a major COVID-19 vaccine. London-listed AstraZeneca said Sarin's appointment was conditional upon the completion of its $39 billion buyouts of Alexion.

Dunoyer will become the U.S. drugmaker's chief executive officer while also being appointed chief strategy officer at AstraZeneca. He will leave the Anglo-Swedish company's board but continue to report to CEO Pascal Soriot.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)